ArticleChest2023
Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis.
Article in Chest, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- An Evidence Map of the Women Veterans' Health Literature, 2016 to 2023: A Systematic Review.JAMA network open · 2025Pooled it
- Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists.Rheumatology advances in practice · 2026Article
- Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2025Review
- Article
- Evaluating Deployment-related Respiratory Diseases in Military Veterans.Annals of the American Thoracic Society · 2025Review
- Differences in disease characteristics and outcomes as determined by biological sex in a large UK idiopathic pulmonary fibrosis population: analysis from the British Thoracic Society, Interstitial Lung Disease registry data.BMJ open respiratory research · 2025Observational
- Caring for Rural Patients With Interstitial Lung Disease: Perspectives of Pulmonary Fibrosis Foundation Care Center Network Nurses and Providers.CHEST pulmonary · 2025Article
- Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study.BMC pulmonary medicine · 2025Article
- Racial disparities in lung function by pulmonary function testing among lung transplant candidates and race-specific reference equations.JHLT open · 2025Article
- Polypharmacy and potentially inappropriate medication (PIM) use among older veterans with idiopathic pulmonary fibrosis (IPF) - a retrospective cohort study.BMC pulmonary medicine · 2025Article
- Health disparities and associated social determinants of health in interstitial lung disease: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.Respiratory research · 2024Article
- Strengthening pharmacotherapy research for COVID-19-induced pulmonary fibrosis.World journal of clinical cases · 2024Article
- Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016-2022.Annals of the American Thoracic Society · 2024Article
- Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundTwo antifibrotic medications, pirfenidone and nintedanib, are approved for the treatment of idiopathic pulmonary fibrosis (IPF). Little is known about their real-world adoption. RESEARCH QUESTION: What are the real-world antifibrotic utilization rates and factors associated with uptake among a national cohort of veterans with IPF? STUDY DESIGN AND
methodsThis study identified veterans with IPF who received care either provided by the Veterans Affairs (VA) Healthcare System or non-VA care paid for by the VA. Patients who had filled at least one antifibrotic prescription through the VA pharmacy or Medicare Part D between October 15, 2014, and December 31, 2019, were identified. Hierarchical logistic regression models were used to examine factors associated with antifibrotic uptake, accounting for comorbidities, facility clustering, and follow-up time. Fine-Gray models were used to evaluate antifibrotic use by demographic factors, accounting for the competing risk of death.
resultsAmong 14,792 veterans with IPF, 17% received antifibrotics. There were significant disparities in adoption, with lower uptake associated with female sex (adjusted OR, 0.41; 95% CI, 0.27-0.63; P < .001), Black race (adjusted OR, 0.60; 95% CI, 0.49-0.73; P < .001), and rural residence (adjusted OR, 0.88; 95% CI, 0.80-0.97; P = .012). Veterans who received their index diagnosis of IPF outside the VA were less likely to receive antifibrotic therapy (adjusted OR, 0.15; 95% CI, 0.10-0.22; P < .001).
interpretationThis study is the first to evaluate the real-world adoption of antifibrotic medications among veterans with IPF. Overall uptake was low, and there were significant disparities in use. Interventions to address these issues deserve further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.